Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lympoblastic Leukemia wit

摘要

For almost 50 years, the use of antimetabolites has been a mainstay for cancer chemotherapy. First and foremost, inhibitors that block DNA synthesis, either by blocking nucleotide synthesis or by reacting with DNA, have been the agents of choice. Not surprisingly, many inhibitors of this type have also been used for the treatment of viral infections. The use of antimetabolites that impair replication stems from the finding that cancer cells frequently replicate more rapidly than the normal cells from which they are derived. hence antimetabolites, which often are nucleotide analogs, are more likely to get incorporated into the chromosome of a cancer cell because its DNA is more likely to be in the process of replication.